Company intelligence / Profile preview

RIME Therapeutics

Cambridge, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Rime Therapeutics is a preclinical-stage biotechnology company dedicated to developing novel small molecule inhibitors of the NLRP3 inflammasome. The company's research focuses on addressing the underlying drivers of chronic inflammation, which are implicated in a wide range of conditions including metabolic, cardiovascular, and neurodegenerative diseases. By targeting the NLRP3 pathway with highly selective and potentially brain-penetrant molecules, Rime aims to provide transformative therapies for patients with high unmet medical needs. The company is led by experienced industry veterans with deep expertise in medicinal chemistry and drug discovery.

Therapeutic areas: ImmunologyNeurology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on RIME Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RIME Therapeutics.

Explore the full profile